Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2024 08:00 ET | Source: Aptose Biosciences, Inc.

Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 14, 2024 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the First Quarter 2024

Aptose Reports Results for the First Quarter 2024
May 06, 2024 16:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
March 26, 2024 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Aptose Reports Results for the Fourth Quarter and Full Year 2023
March 18, 2024 16:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
January 31, 2024 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

Aptose closes previously announced public offering and private placement
January 26, 2024 08:00 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
December 09, 2023 18:30 ET | Source: Aptose Biosciences, Inc.

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

ASH Oral Presentation: Complete Response Data from the Ongoing APTIVATE Phase 1/2 Study of Tuspetinib (TUS) in R/R AML Patients
November 30, 2023 16:59 ET | Source: Aptose Biosciences, Inc.

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
November 09, 2023 16:00 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the Third Quarter 2023

Aptose Reports Results for the Third Quarter 2023 • TUS/VEN Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right